Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results.
about
The clinical relevance of pre-formed anti-HLA and anti-MICA antibodies after cord blood transplantation in children.Glutathione S-transferase A1 genetic variants reduce busulfan clearance in children undergoing hematopoietic cell transplantation.Influence of glutathione S-transferase gene polymorphisms on busulfan pharmacokinetics and outcome of hematopoietic stem-cell transplantation in thalassemia pediatric patientsPrediction of drug clearance in children: a review of different methodologies.Glutathione S-transferase gene variations influence BU pharmacokinetics and outcome of hematopoietic SCT in pediatric patients.Monitoring of Busulphan Concentrations in Children Undergone Hematopoietic Stem Cell Transplantation: Unicentric Experience over 10 years.A Nonparametric Method to Optimize Initial Drug Dosing and Attainment of a Target Exposure Interval: Concepts and Application to Busulfan in Pediatrics.Can the pharmacogenetics of GST gene polymorphisms predict the dose of busulfan in pediatric hematopoietic stem cell transplantation?Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity.Transplantation of allogeneic CD34-selected stem cells after fludarabine-based conditioning regimen for children with mucopolysaccharidosis 1H (M. Hurler).The pharmacokinetics and safety of twice daily i.v. BU during conditioning in pediatric allo-SCT recipients.Influence of GST gene polymorphisms on busulfan pharmacokinetics in children.Age-dependent pharmacokinetic profile of single daily dose i.v. busulfan in children undergoing reduced-intensity conditioning stem cell transplant.Prospective pharmacokinetic study of intravenous busulfan in hematopoietic stem cell transplantation in 25 children.Busulphan-loaded long-circulating nanospheres, a very attractive challenge for both galenists and pharmacologists.Pharmacokinetics-adapted Busulfan-based myeloablative conditioning before unrelated umbilical cord blood transplantation for myeloid malignancies in children.
P2860
Q34973409-D5457755-AACD-4876-AF96-AE6BDD144202Q35486314-DE045D33-13C8-4BF9-A5CA-D405C117E0A4Q36650481-28472E0A-5394-4C15-AECC-7B36117E36B7Q38367747-13F6ADEC-08F5-47E4-A6CB-D058D91ABFF1Q39490930-8B09DB90-E011-413C-BEDD-AFA3CA1C34A5Q40085411-F6B20157-70C4-4185-B93A-45F540719F18Q40554814-744AAE89-7A7C-41BF-9D3F-F2EC81BC7016Q43248045-A00D0C94-D49A-4BFE-8C1A-41999C0B5892Q45122639-341ACEE8-AF3F-4FE1-BE69-BF438B1289C9Q45174143-E99AEA91-1C10-45B8-B10D-23930288BED9Q45805141-993CC07E-5BD2-44DF-B949-9DBB7D926F31Q45936278-04B24D0F-6003-4978-9724-DDF444C0A780Q46138906-125D1D0A-1D9B-4B27-8D7C-028B127A3544Q46359750-DC0803A4-CB39-448D-A319-149B68583F0DQ46958507-824AD693-2D56-43D5-AD00-A7CB92BBEEF8Q52613271-89B998D1-6DA3-470B-AE3F-6D3DEA08B057
P2860
Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Intravenous busulfan for allog ...... l and pharmacokinetic results.
@en
Intravenous busulfan for allog ...... l and pharmacokinetic results.
@nl
type
label
Intravenous busulfan for allog ...... l and pharmacokinetic results.
@en
Intravenous busulfan for allog ...... l and pharmacokinetic results.
@nl
prefLabel
Intravenous busulfan for allog ...... l and pharmacokinetic results.
@en
Intravenous busulfan for allog ...... l and pharmacokinetic results.
@nl
P2093
P2860
P356
P1476
Intravenous busulfan for allog ...... l and pharmacokinetic results.
@en
P2093
D Larocque
J Gardiner
M A Champagne
M F Vachon
P2860
P2888
P304
P356
10.1038/SJ.BMT.1704209
P407
P577
2003-10-01T00:00:00Z